ClinicalTrials.gg
CompletedNCT00282048Updated Jul 31, 2012Results posted

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

A Phase 2 interventional study of AG-013736 (axitinib) in Kidney Neoplasms and Carcinoma, Renal Cell, sponsored by Pfizer. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-31.

Primary conditionCarcinoma, Renal CellRegistry: Kidney NeoplasmsReclassifiedWhy we changed it
Registry
Kidney Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Renal Cell
Why
  1. The study's listed conditions name Carcinoma, Renal Cell, a narrower term within Kidney Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.

Enrollment
13th of 41
62 · median 40
Started
2006
the only one that year
Phase 2
29 of 41
9 open now
Registered
1st of 41
by date
Lead sponsor
6 of 41
Pfizer

Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 13th largest by enrollment, is the only one that started in 2006, is one of 29 in phase 2, and was the 1st registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About axitinib

Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing axitinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

03

Conditions studied

  • Kidney Neoplasms
  • Carcinoma, Renal Cell

Browse trials for

04

In context

Carcinoma, Renal Cell Reclassified

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

This study's enrollment of 62 is above the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.

Browse Carcinoma, Renal Cell studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Carcinoma, Renal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • RCC with and nephrectomy
  • failure of prior sorafenib-based therapy
  • at least 1 target lesion that has not been irradiated
  • adequate bone marrow, hepatic and renal function, > or equal to 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Gastrointestinal abnormalities
  • current use or inability to avoid chronic antacid therapy
  • current use or anticipated inability to avoid potent inhibitors or CYP1A2 inducers
  • active seizure disorder or evidence of .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    AG-013736 (axitinib)

    AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity

    Drug: AG-013736 (axitinib)

Interventions

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of responses. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.

    Time frame: Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 152 weeks

Secondary outcomes

  1. Progression-free Survival (PFS)

    Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 152 weeks

  2. Duration of Response (DR)

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 152 weeks

  3. Overall Survival (OS)

    Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.

    Time frame: Baseline to death due to any cause or at least 1 year after the first dose for the last participant

  4. Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index for Disease Cancer Related Symptoms (FKSI-DRS) Score

    FKSI-DRS is a subset of FKSI which is a questionnaire for FACT -Kidney Symptom Index used to assess Quality of Life (QoL)/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions and the FKSI-DRS consisted of 9 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI-DRS ranged between 0-36. Since the questions could be reversed coded, as appropriate, before calculating FKSI-DRS, 0 and 36 could be considered the worst and best health states based on the 9 questions comprising FKSI-DRS.

    Time frame: Baseline (Day 1 of Cycle 1), Day 1 of all subsequent cycles up to Cycle 38 and follow up (28 days after last dose)

  5. Population Pharmacokinetics of Axitinib (AG-013736)

    Data for this outcome measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 1 (Pre-dose), Day 29, Day 57 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks

Other outcomes

  1. Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index (FKSI) Score

    FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms.

    Time frame: Baseline (Day 1 of Cycle 1), Day 1 of all subsequent cycles up to Cycle 38 and follow up (28 days after last dose)

  2. Correlation of Area Under the Concentration-time Curve at Steady State (AUCss) With Confirmed Partial Response (PR)

    AUCss: pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods, computed as each participant's average total daily dose (accounting for dose reductions and any recorded missed doses) divided by population estimated posthoc individual apparent clearance (CL/F), i.e., AUCss = Daily Dose/(CL/F), where F refers to the oral bioavailability, and CL refers to the systemic clearance. PR: responses with at least 30% decrease in sum of longest dimensions of target lesions using baseline (pre-treatment) sum of longest dimensions as reference. Logistic regression with general linear model was applied to data of PR using AUCss; PR was correlated with AUCss as fold increase in odds of PR with increase in AUCss. Fold increase was calculated as exponent of product of logistic regression slope coefficient and unit change of AUCss.

    Time frame: Day 1 (Pre-dose), Day 29 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks

  3. Relationship of Area Under the Concentration-time Curve at Steady State (AUCss) With Progression-free Survival (PFS)

    AUCss is a pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods. PFS is median time from first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. Relationship of PFS versus AUCss was determined as median PFS in participants with high AUCss \[AUCss greater than or equal to (\>=) median AUCss\] or low AUCss \[AUCss less than (\<) median AUCss\].

    Time frame: Day 1 (Pre-dose), Day 29, and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks

  4. Relationship of Area Under the Concentration-time Curve at Steady State (AUCss) With Overall Survival (OS)

    AUCss is a pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods. OS is time in weeks from the start of study treatment to date of death due to any cause. Relationship of OS versus AUCss was determined as median OS in participants with high AUCss \[AUCss \>= median AUCss\] or low AUCss \[AUCss \< median AUCss\].

    Time frame: Day 1 (Pre-dose), Day 29 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks

08

Results

Posted Apr 3, 2012
Limitations and caveats
Population pharmacokinetics was not presented, as the data was not available for the single study and data of other axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.

Participant flow

Participant flow — Overall Study
MilestoneAxitinib
Started62
Completed0
Not completed62
Withdrew: Lack of efficacy30
Withdrew: Adverse event22
Withdrew: Withdrawal by subject1
Withdrew: Other8
Withdrew: Ongoing1

Outcome measures

PrimaryPercentage of Participants With Objective Response (OR)

Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of responses. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.

Time frame:
Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 152 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response (OR)
Percentage of ParticipantsAxitinib
Percentage of Participants With Objective Response (OR)22.6 (12.9 to 35.0)
SecondaryProgression-free Survival (PFS)

Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 152 weeks
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysAxitinib
Progression-free Survival (PFS)225 (203 to 334)
SecondaryDuration of Response (DR)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 152 weeks
Reported as:
Median · Days
Duration of Response (DR)
DaysAxitinib
Duration of Response (DR)531 (225 to NA)
SecondaryOverall Survival (OS)

Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.

Time frame:
Baseline to death due to any cause or at least 1 year after the first dose for the last participant
Reported as:
Median · Days
Overall Survival (OS)
DaysAxitinib
Overall Survival (OS)412.5 (256.0 to 570.0)
SecondaryFunctional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index for Disease Cancer Related Symptoms (FKSI-DRS) Score

FKSI-DRS is a subset of FKSI which is a questionnaire for FACT -Kidney Symptom Index used to assess Quality of Life (QoL)/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions and the FKSI-DRS consisted of 9 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI-DRS ranged between 0-36. Since the questions could be reversed coded, as appropriate, before calculating FKSI-DRS, 0 and 36 could be considered the worst and best health states based on the 9 questions comprising FKSI-DRS.

Time frame:
Baseline (Day 1 of Cycle 1), Day 1 of all subsequent cycles up to Cycle 38 and follow up (28 days after last dose)
Reported as:
Mean · Units on a Scale
Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index for Disease Cancer Related Symptoms (FKSI-DRS) Score
Units on a ScaleAxitinib
Baseline (n=62)28.94 (27.69 to 30.19)
Day 1 (Cycle 2) (n=52)27.12 (25.76 to 28.47)
Day 1 (Cycle 3) (n=46)27.11 (25.79 to 28.43)
Day 1 (Cycle 4) (n=41)27.68 (26.21 to 29.16)
Day 1 (Cycle 5) (n=39)27.94 (26.55 to 29.34)
Day 1 (Cycle 6) (n=33)27.31 (25.52 to 29.11)
Day 1 (Cycle 7) (n=32)28.56 (26.79 to 30.33)
Day 1 (Cycle 8) (n=30)28.55 (26.58 to 30.53)
Day 1 (Cycle 9) (n=27)28.75 (27.05 to 30.44)
Day 1 (Cycle 10) (n=19)29.37 (27.40 to 31.34)
Day 1 (Cycle 11) (n=17)29.35 (27.13 to 31.57)
Day 1 (Cycle 12) (n=17)29.24 (26.67 to 31.80)
Day 1 (Cycle 13) (n=16)30.41 (28.27 to 32.56)
Day 1 (Cycle 14) (n=15)31.02 (29.56 to 32.47)
Day 1 (Cycle 15) (n=14)30.29 (28.48 to 32.09)
Day 1 (Cycle 16) (n=14)30.79 (28.88 to 32.70)
Day 1 (Cycle 17) (n=13)31.46 (29.10 to 33.82)
Day 1 (Cycle 18) (n=12)31.08 (29.20 to 32.97)
Day 1 (Cycle 19) (n=9)29.44 (26.72 to 32.17)
Day 1 (Cycle 20) (n=10)29.80 (27.87 to 31.73)
Day 1 (Cycle 21) (n=11)29.91 (26.71 to 33.11)
Day 1 (Cycle 22) (n=10)30.80 (27.88 to 33.72)
Day 1 (Cycle 23) (n=9)30.22 (25.74 to 34.70)
Day 1 (Cycle 24) (n=8)31.75 (28.76 to 34.74)
Day 1 (Cycle 25) (n=7)31.14 (27.58 to 34.70)
Day 1 (Cycle 26) (n=7)31.29 (27.76 to 34.82)
Day 1 (Cycle 27) (n=7)32.00 (28.08 to 35.92)
Day 1 (Cycle 28) (n=5)34.00 (31.37 to 36.63)
Day 1 (Cycle 29) (n=6)33.83 (31.49 to 36.17)
Day 1 (Cycle 30) (n=6)34.00 (30.82 to 37.18)
Day 1 (Cycle 31) (n=4)33.75 (28.49 to 39.01)
Day 1 (Cycle 32) (n=1)34.00 (NA to NA)
Day 1 (Cycle 33) (n=1)34.00 (NA to NA)
Day 1 (Cycle 34) (n=0)NA (NA to NA)
Day 1 (Cycle 35) (n=1)33.00 (NA to NA)
Day 1 (Cycle 36) (n=1)33.00 (NA to NA)
Day 1 (Cycle 37) (n=1)29.00 (NA to NA)
Day 1 (Cycle 38) (n=1)30.00 (NA to NA)
at Follow Up (n=9)25.11 (20.64 to 29.58)
SecondaryPopulation Pharmacokinetics of Axitinib (AG-013736)

Data for this outcome measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 1 (Pre-dose), Day 29, Day 57 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks
Reported as:
Mean · nanogram/milliliter (ng/mL)

Results for this outcome have not been posted.

Other pre-specifiedFunctional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index (FKSI) Score

FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms.

Time frame:
Baseline (Day 1 of Cycle 1), Day 1 of all subsequent cycles up to Cycle 38 and follow up (28 days after last dose)
Reported as:
Mean · Units on a Scale
Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index (FKSI) Score
Units on a ScaleAxitinib
Baseline (n=62)44.84 (42.65 to 47.03)
Day 1 (Cycle 2) (n=52)41.40 (39.13 to 43.67)
Day 1 (Cycle 3) (n=46)41.62 (39.28 to 43.97)
Day 1 (Cycle 4) (n=41)42.26 (39.55 to 44.97)
Day 1 (Cycle 5) (n=39)42.35 (39.85 to 44.84)
Day 1 (Cycle 6) (n=33)41.65 (38.82 to 44.49)
Day 1 (Cycle 7) (n=32)43.77 (41.09 to 46.45)
Day 1 (Cycle 8) (n=30)44.00 (40.75 to 47.25)
Day 1 (Cycle 9) (n=27)44.80 (41.84 to 47.76)
Day 1 (Cycle 10) (n=19)45.39 (41.82 to 48.95)
Day 1 (Cycle 11) (n=17)44.14 (40.23 to 48.06)
Day 1 (Cycle 12) (n=17)44.73 (40.79 to 48.67)
Day 1 (Cycle 13) (n=16)46.13 (42.19 to 50.06)
Day 1 (Cycle 14) (n=15)47.04 (43.94 to 50.14)
Day 1 (Cycle 15) (n=14)45.93 (42.67 to 49.20)
Day 1 (Cycle 16) (n=14)46.16 (41.96 to 50.36)
Day 1 (Cycle 17) (n=13)48.14 (44.18 to 52.10)
Day 1 (Cycle 18) (n=12)47.08 (42.43 to 51.72)
Day 1 (Cycle 19) (n=9)44.98 (39.24 to 50.71)
Day 1 (Cycle 20) (n=10)45.81 (41.41 to 50.20)
Day 1 (Cycle 21) (n=11)47.02 (40.99 to 53.05)
Day 1 (Cycle 22) (n=10)47.50 (42.06 to 52.94)
Day 1 (Cycle 23) (n=9)46.30 (38.77 to 53.83)
Day 1 (Cycle 24) (n=8)48.64 (42.38 to 54.91)
Day 1 (Cycle 25) (n=7)49.11 (44.46 to 53.77)
Day 1 (Cycle 26) (n=7)50.26 (45.32 to 55.19)
Day 1 (Cycle 27) (n=7)49.82 (43.61 to 56.02)
Day 1 (Cycle 28) (n=5)53.20 (46.55 to 59.85)
Day 1 (Cycle 29) (n=6)52.67 (45.84 to 59.49)
Day 1 (Cycle 30) (n=6)53.17 (46.26 to 60.08)
Day 1 (Cycle 31) (n=4)53.00 (40.74 to 65.26)
Day 1 (Cycle 32) (n=1)53.00 (NA to NA)
Day 1 (Cycle 33) (n=1)51.00 (NA to NA)
Day 1 (Cycle 34) (n=0)NA (NA to NA)
Day 1 (Cycle 35) (n=1)51.00 (NA to NA)
Day 1 (Cycle 36) (n=1)51.00 (NA to NA)
Day 1 (Cycle 37) (n=1)45.00 (NA to NA)
Day 1 (Cycle 38) (n=1)48.00 (NA to NA)
At Follow Up (n=9)38.98 (32.46 to 45.49)
Other pre-specifiedCorrelation of Area Under the Concentration-time Curve at Steady State (AUCss) With Confirmed Partial Response (PR)

AUCss: pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods, computed as each participant's average total daily dose (accounting for dose reductions and any recorded missed doses) divided by population estimated posthoc individual apparent clearance (CL/F), i.e., AUCss = Daily Dose/(CL/F), where F refers to the oral bioavailability, and CL refers to the systemic clearance. PR: responses with at least 30% decrease in sum of longest dimensions of target lesions using baseline (pre-treatment) sum of longest dimensions as reference. Logistic regression with general linear model was applied to data of PR using AUCss; PR was correlated with AUCss as fold increase in odds of PR with increase in AUCss. Fold increase was calculated as exponent of product of logistic regression slope coefficient and unit change of AUCss.

Time frame:
Day 1 (Pre-dose), Day 29 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks
Reported as:
Number · Ratio
Correlation of Area Under the Concentration-time Curve at Steady State (AUCss) With Confirmed Partial Response (PR)
RatioAxitinib
Fold change per 1 ng*hr/mL: Cycle11.0028
Fold change per 100 ng*hr/mL: Cycle11.3300
Other pre-specifiedRelationship of Area Under the Concentration-time Curve at Steady State (AUCss) With Progression-free Survival (PFS)

AUCss is a pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods. PFS is median time from first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. Relationship of PFS versus AUCss was determined as median PFS in participants with high AUCss \[AUCss greater than or equal to (\>=) median AUCss\] or low AUCss \[AUCss less than (\<) median AUCss\].

Time frame:
Day 1 (Pre-dose), Day 29, and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks
Reported as:
Median · weeks
Relationship of Area Under the Concentration-time Curve at Steady State (AUCss) With Progression-free Survival (PFS)
weeksAxitinib
PFS at Low AUCss: Cycle1 (n=28)31 (24 to 80)
PFS at High AUCss: Cycle1 (n=29)39 (31 to NA)
Other pre-specifiedRelationship of Area Under the Concentration-time Curve at Steady State (AUCss) With Overall Survival (OS)

AUCss is a pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods. OS is time in weeks from the start of study treatment to date of death due to any cause. Relationship of OS versus AUCss was determined as median OS in participants with high AUCss \[AUCss \>= median AUCss\] or low AUCss \[AUCss \< median AUCss\].

Time frame:
Day 1 (Pre-dose), Day 29 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks
Reported as:
Median · weeks
Relationship of Area Under the Concentration-time Curve at Steady State (AUCss) With Overall Survival (OS)
weeksAxitinib
OS at Low AUCss: Cycle1 (n=28)43 (36 to 72)
OS at High AUCss: Cycle1 (n=29)88 (73 to NA)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib—39/62 (62.9%)62/62 (100%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventAxitinib
DyspnoeaRespiratory, thoracic and mediastinal disorders7/62
DehydrationMetabolism and nutrition disorders6/62
Abdominal painGastrointestinal disorders5/62
HypotensionVascular disorders5/62
NauseaGastrointestinal disorders4/62
VomitingGastrointestinal disorders4/62
Disease progressionGeneral disorders4/62
HypertensionVascular disorders3/62
Cardiac failure congestiveCardiac disorders2/62
Myocardial ischaemiaCardiac disorders2/62
Most frequent other events
Showing 10 of 227
Most frequent other events
EventAxitinib
FatigueGeneral disorders47/62
DiarrhoeaGastrointestinal disorders38/62
Decreased appetiteMetabolism and nutrition disorders33/62
NauseaGastrointestinal disorders27/62
HypertensionVascular disorders26/62
DysphoniaRespiratory, thoracic and mediastinal disorders23/62
Mucosal inflammationGeneral disorders21/62
DyspnoeaRespiratory, thoracic and mediastinal disorders21/62
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders21/62
VomitingGastrointestinal disorders19/62

Baseline characteristics

Age Continuous
Age Continuous(Years)Axitinib
Mean57.9 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib
Female20
Male42
09

Study locations

5 sites
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    Bronx, New York 10466, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19111-2497, United States
  • Pfizer Investigational Site
    Madison, Wisconsin 53792, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Feb 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 3 years 2 months after primary completion. A results delay was requested in May 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2006
First posted
Jan 25, 2006
Start
Mar 2006
Primary completionActual
Feb 2009
CompletionActual
Jun 2009
Results delay requested
May 20, 2009
Results first posted
Apr 3, 2012
Last update
Jul 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00282048
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 25, 2006
Start date
Mar 2006
Primary completion
Feb 2009
Completion
Jun 2009
Results posted
Apr 3, 2012
Last update
Jul 31, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion